Medicine in DR Congo · official US FDA label
Natamycine 5 %
Natamycine (natamycin) · suspension
Want to buy it?
Not in stock in our pharmacies right now. Trouver shows when it is back near you. The reservation pages are in French.
This is a US label.
The official US FDA label for natamycin, effective November 5, 2025, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.
Official US FDA label for natamycin
Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.
Uses
INDICATIONS AND USAGE: NATACYN ® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established.
Dosage
US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.
DOSAGE AND ADMINISTRATION: SHAKE WELL BEFORE USING. The preferred initial dosage in fungal keratitis is one drop of NATACYN ® (natamycin ophthalmic suspension) 5% instilled in the conjunctival sac at hourly or two-hourly intervals. The frequency of application can usually be reduced to one drop 6 to 8 times daily after the first 3 to 4 days. Therapy should generally be continued for 14 to 21 days or until there is resolution of active fungal keratitis. In many cases, it may be helpful to reduce the dosage gradually at 4 to 7 day intervals to assure that the replicating organism has been eliminated. Less frequent initial dosage (4 to 6 daily applications) may be sufficient in fungal blepharitis and conjunctivitis.
Side effects
ADVERSE REACTIONS: The following events have been identified during post-marketing use of NATACYN ® (natamycin ophthalmic suspension) 5% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to their seriousness, frequency of reporting, possible causal connection to NATACYN ® (natamycin ophthalmic suspension) 5%, or a combination of these factors include: allergic reaction, change in vision, chest pain, corneal opacity, dyspnea, eye discomfort, eye edema, eye hyperemia, eye irritation, eye pain, foreign body sensation, parethesia, and tearing.
Where to find it in DR Congo
Not in stock in our pharmacies right now
Stock changes with every sale. Search by substance: a medicine with the same composition may be available.
Composition
| Substance | Strength | ATC code |
|---|---|---|
| Natamycine (natamycin) | 5 % | — |
Sources
- ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
- ●English names of substances: RxNorm, U.S. National Library of Medicine.
- ●Essential medicines: national list of essential medicines of DR Congo (LNME).
Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.